As a clinical pharmacokineticist, A/Prof Stephanie Reuter Lange’s research portfolio broadly focusses on using pharmacological principles to inform the optimal use of medications. Appropriately, through this activity she works extensively with pharmaceutical industry and regulatory agencies in the development of new drug entities, as well as clinicians and pharmacists to improve the use of existing drugs for better management of patients in clinical practice. Her research philosophy is one of translation, specifically bridging the interface between foundational science and clinical practice, acting as a conduit between science, policy and the clinic.
About me
As a clinical pharmacokineticist, A/Prof Stephanie Reuter Lange’s research portfolio broadly focusses on using pharmacological principles to inform the optimal use of medications. Appropriately, through this activity she works extensively with pharmaceutical industry and regulatory agencies in the development of new drug entities, as well as clinicians and pharmacists to improve the use of existing drugs for better management of patients in clinical practice. Her research philosophy is one of translation, specifically bridging the interface between foundational science and clinical practice, acting as a conduit between science, policy and the clinic.
About me
Doctor of Philosophy University of South Australia
Bachelor of Science (Honours) The University of Adelaide
Stephanie currently holds Cancer Council Mid-Career Fellowship, which aims to address the medication issues associated with the sub-optimal use of anti-cancer agents and develop rational, evidence-based guidelines for the appropriate prescription of these drugs in clinical practice. She has previously been awarded a prestigious Fulbright Visiting Research Scholarship to undertake research with world leaders in the field of PK/PD modelling at the State University of New York, using innovative techniques to inform the quality use of medicines.
Research
Excludes commercial-in-confidence projects.
Neoculi | Pharmacokinetic Analysis & Reporting - A GSP pharmacokinetic study in dogs comparing two investigational veterinary products administered via the intravenous and oral routes, Neoculi Pty Ltd, 28/08/2023 - 27/08/2026
Optimising Cancer Therapy through Development of Evidence-Based Dose Individualisation Strategies, Cancer Council SA Research Fellowship, 01/07/2020 - 30/06/2023
The buccal administration of a Cannabis sativa L./Cannabis indica L. extract as an adjunct to opioid analgesia for the management of intractable pain in patients diagnosed with advanced cancer., Medlab Clinical Ltd, 01/07/2020 - 30/06/2022
PK analysis research services for clinical study DTX-SPL8783, Starpharma, 04/07/2016 - 30/12/2020
PK & PD biostatistical studies, TetraQ, 09/10/2014 - 31/12/2019
Literature Review of International Biosimilar Medicines, Cwth Dept of Health Aged Care, 01/03/2016 - 30/06/2018
PK and PD research advice, Prana Biotechnology, 25/09/2014 - 31/12/2017
Improving the therapeutic use of anti-infective agents: Application of pharmacometrics for rational dosing regimen design, NHMRC - Early Career Fellowship, 13/05/2013 - 12/05/2017
Research
Research outputs for the last seven years are shown below. Some long-standing staff members may have older outputs included. To see earlier years visit ORCID, ResearcherID or Scopus
Open access indicates that an output is open access.
Year | Output |
---|---|
2024 |
1
|
2024 |
Open access
|
2024 |
2
2
15
|
2024 |
Open access
3
|
2024 |
|
2024 |
Open access
|
2024 |
1
|
2023 |
Open access
1
|
2023 |
10
10
34
|
2023 |
Open access
2
2
3
|
2023 |
Open access
5
4
20
|
2023 |
Open access
5
|
2023 |
Open access
2
|
2023 |
Open access
2
3
|
2022 |
Open access
5
11
1
|
2022 |
23
25
9
|
2022 |
|
2022 |
Open access
9
9
2
|
2022 |
Open access
2
2
7
|
2021 |
13
13
33
|
2021 |
Open access
32
28
3
|
2021 |
Open access
5
4
306
|
2021 |
12
13
1
|
2021 |
5
5
8
|
2021 |
Open access
6
5
1
|
2021 |
Open access
15
15
5
|
2020 |
Open access
3
3
2
|
2020 |
Open access
41
41
11
|
2020 |
19
20
7
|
2020 |
4
6
110
|
2019 |
Open access
8
7
4
|
2019 |
7
7
4
|
2019 |
Open access
8
8
|
2019 |
Open access
4
4
1
|
2019 |
Open access
2
3
4
|
2019 |
14
12
3
|
2018 |
Open access
13
12
6
|
2016 |
Open access
35
32
2
|
2016 |
6
5
|
2015 |
Open access
21
21
1
|
2014 |
Open access
21
17
28
|
2014 |
Open access
15
15
1
|
2012 |
Open access
352
338
|
2012 |
2
2
|
2011 |
49
44
|
2011 |
Open access
38
33
|
2010 |
Open access
|
2009 |
Open access
33
31
|
2008 |
50
48
|
2008 |
28
28
|
Year | Output |
---|---|
2021 |
Open access
|
2020 |
Open access
|
2020 |
Open access
|
2020 |
Open access
|
2020 |
Open access
|
2019 |
Open access
|
2019 |
Open access
|
2019 |
Open access
|
2019 |
Open access
|
2018 |
Open access
|
2018 |
Open access
|
2018 |
Open access
|
2017 |
Open access
|
2017 |
Open access
|
2017 |
Open access
|
2017 |
Open access
|
2016 |
Open access
|
2016 |
Open access
|
2016 |
Open access
|
Research
Stephanie currently holds Cancer Council Mid-Career Fellowship, which aims to address the medication issues associated with the sub-optimal use of anti-cancer agents and develop rational, evidence-based guidelines for the appropriate prescription of these drugs in clinical practice. She has previously been awarded a prestigious Fulbright Visiting Research Scholarship to undertake research with world leaders in the field of PK/PD modelling at the State University of New York, using innovative techniques to inform the quality use of medicines.
Stephanie is a strong advocate for the importance of engagement and scientific communication to facilitate higher rates of research translation. She makes it a priority to engage end-users throughout the research process to maximise research outcomes and contribute significantly to health research within Australia and internationally. Stephanie also contributes widely to both the scientific and general communities through her involvement on a number of professional committees, dissemination of research findings to the public and promotion of careers in science. In acknowledgment of her scientific engagement and research significance, she has been awarded a Tall Poppy Award and two SA Science Excellence Awards.
External engagement & recognition
Organisation | Country |
---|---|
ASST Fatebenefratelli Sacco University Hospital | ITALY |
Bod Australia Pty Ltd. | AUSTRALIA |
Centre for Health Studies | LUXEMBOURG |
Charles Darwin University | AUSTRALIA |
Christian Medical College | INDIA |
CMAX | AUSTRALIA |
Concord Repatriation General Hospital | AUSTRALIA |
Cpr Pharma Services Pty Ltd | AUSTRALIA |
Drugs for Neglected Diseases initiative (DNDI) | SWITZERLAND |
Erasmus MC, Rotterdam | NETHERLANDS |
Flinders Medical Centre | AUSTRALIA |
Flinders University | AUSTRALIA |
Fondazione IRCCS Policlinico San Matteo | ITALY |
Ghent University | BELGIUM |
Hospital for Tropical Disease | THAILAND |
Hunter Medical Research Institute, Australia | AUSTRALIA |
Hunter Pathology | AUSTRALIA |
Medicines for Malaria Venture | SWITZERLAND |
Monash University | AUSTRALIA |
National Human Genome Research Institute | UNITED STATES |
Northern Territory Department of Health | AUSTRALIA |
Ohio State University | UNITED STATES |
Pediatrix Screening | UNITED STATES |
Pfizer Australia Pty Ltd | AUSTRALIA |
Prince of Wales Hospital | AUSTRALIA |
Princess Alexandra Hospital | AUSTRALIA |
QIMR Berghofer Medical Research Institute | AUSTRALIA |
Q-Pharm | AUSTRALIA |
Royal Adelaide Hospital | AUSTRALIA |
Royal North Shore Hospital | AUSTRALIA |
Sigma-Tau Industrie Farmaceutiche Riunite | ITALY |
St Vincent’s Hospital | AUSTRALIA |
St Vincents Hospital | UNITED STATES |
St Vincent's Hospital | AUSTRALIA |
St Vincents Hospital Sydney | AUSTRALIA |
St Vincent's Hospital Sydney | AUSTRALIA |
Swiss BioQuant | SWITZERLAND |
Sydney Medical School | AUSTRALIA |
Taylor's University | MALAYSIA |
TetraQ | AUSTRALIA |
The Queen Elizabeth Hospital | AUSTRALIA |
The University of Notre Dame Australia | AUSTRALIA |
University Hospital of Ghent | BELGIUM |
University of Adelaide | AUSTRALIA |
University of Cape Town | SOUTH AFRICA |
University of Groningen | NETHERLANDS |
University of Hamburg | GERMANY |
University of New South Wales | AUSTRALIA |
University of Newcastle | AUSTRALIA |
University of Oxford | UNITED KINGDOM |
University of Science, Malaysia | MALAYSIA |
University of South Australia | AUSTRALIA |
University of Southern California | UNITED STATES |
University of Sydney | AUSTRALIA |
University of Technology Sydney | AUSTRALIA |
University of Wollongong | AUSTRALIA |
Utrecht University | NETHERLANDS |
Van Giersbergen Consulting | FRANCE |
Westmead Hospital | AUSTRALIA |
Women's and Children's Hospital | AUSTRALIA |
World Bank | UNITED STATES |
External engagement & recognition
Engagement/recognition | Year |
---|---|
Co-Chair : Academic SubcommitteePharmaceutical Society of Australia |
2021 |
Council Member, Executive CommitteeAustralasian Pharmaceutical Science Association (APSA) |
2021 |
Executive EditorBritish Journal of Clinical Pharmacology |
2021 |
Member, Anti-Infectives CommitteeInternational Association of Therapeutic Drug Monitoring and Clinical Toxicology |
2021 |
Scientific Expert ReviewerBellberry Human Research Ethics Committee |
2021 |
Certara New Investigator, Early Career Researcher AwardAustralasian Society of Clinical and Experimental Pharmacologists and Toxicologists (ASCEPT) |
2020 |
Co-Chair : Academic SubcommitteePharmaceutical Society of Australia |
2020 |
Council Member, Executive CommitteeAustralasian Pharmaceutical Science Association (APSA) |
2020 |
Executive EditorBritish Journal of Clinical Pharmacology |
2020 |
Member, Anti-Infectives CommitteeInternational Association of Therapeutic Drug Monitoring and Clinical Toxicology |
2020 |
Member, Board of Pharmaceutical SciencesInternational Pharmaceutical Federation (FIP) |
2020 |
Member, Steering Committee, Personalised and Precision MedicineInternational Pharmaceutical Federation (FIP) |
2020 |
PresidentAustralasian Pharmaceutical Sciences Association |
2020 |
Scientific Expert ReviewerBellberry Human Research Ethics Committee |
2020 |
Co-Chair : Academic SubcommitteePharmaceutical Society of Australia |
2019 |
Council Member, Executive CommitteeAustralasian Pharmaceutical Science Association (APSA) |
2019 |
Member, Board of Pharmaceutical SciencesInternational Pharmaceutical Federation (FIP) |
2019 |
Member, Steering Committee, Personalised and Precision MedicineInternational Pharmaceutical Federation (FIP) |
2019 |
PresidentAustralasian Pharmaceutical Sciences Association |
2019 |
Scientific Expert ReviewerBellberry Human Research Ethics Committee |
2019 |
Council Member, Executive CommitteeAustralasian Pharmaceutical Science Association (APSA) |
2018 |
Member, Board of Pharmaceutical SciencesInternational Pharmaceutical Federation (FIP) |
2018 |
Member, Steering Committee, Personalised and Precision MedicineInternational Pharmaceutical Federation (FIP) |
2018 |
PresidentAustralasian Pharmaceutical Sciences Association |
2018 |
Scientific Expert ReviewerBellberry Human Research Ethics Committee |
2018 |
Bellberry Human Research Ethics CommitteeBellberry Human Research Ethics Committee |
2017 |
Council Member, Executive CommitteeAustralasian Pharmaceutical Science Association (APSA) |
2017 |
Member, Board of Pharmaceutical SciencesInternational Pharmaceutical Federation (FIP) |
2017 |
PresidentAustralasian Pharmaceutical Sciences Association |
2017 |
PresidentAustralasian Pharmaceutical Science Association (APSA) |
2017 |
Scientific Expert ReviewerBellberry Human Research Ethics Committee |
2017 |
Council Member, Executive CommitteeAustralasian Pharmaceutical Science Association (APSA) |
2016 |
Scientific Expert ReviewerBellberry Human Research Ethics Committee |
2016 |
Scientific Expert ReviewerBellberry Human Research Ethics Committee |
2015 |
Finalist, Tall Poppy AwardAustralian Institute of Policy and Science |
2014 |
Peoples Choice, SA Science Excellence AwardsDepartment of State Development, Government of South Australia |
2014 |
Scientific Expert ReviewerBellberry Human Research Ethics Committee |
2014 |
Early Career FellowshipNational Health and Medical Research Council (NHMRC) |
2013 |
Scientific Expert ReviewerBellberry Human Research Ethics Committee |
2013 |
Fulbright Visiting Researcher ScholarshipAustralian-American Fulbright Commission |
2012 |
PhD Research Excellence Award, Health and Medical ScienceDepartment of State Development, Government of South Australia |
2012 |
As a research-focussed academic, Stephanie values the opportunity to contribute to undergraduate teaching of physiology and pharmacology. She recognises the importance of these core subjects and aims to produce students with a sound body of knowledge that forms the foundation of their subsequent learning. Stephanie also has an interest in the teaching of biostatistics, specifically removing the stigma associated with this complex topic and providing education in a manner that is more accessible and usable for all researchers.
Teaching & student supervision
Teaching & student supervision
Supervisions from 2010 shown
Thesis title | Student status |
---|---|
Application of pharmacokinetic modelling to develop a dosing decision support tool to optimise vancomycin dosing in practice | Current |
Optimising treatment of haematological malignancies through the development of evidence-based dose individualisation strategies | Current |
Optimising vancomycin treatment in paediatric patients | Current |
Pharmacogenomics to achieve precision dosing of fluoropyrimidines (FP) in cancer patients | Current |
Validate and optimization of Aminoglycoside Therapeutic Drug Monitoring in children and adults. | Current |
Liquid chromatography-tandem mass spectrometry-based bioanalysis to assess toxicological and therapeutic aspects in human disease conditions | Completed |
Pharmacometric methodologies and their use for lenalidomide drug development in chronic lymphocytic leukaemia | Completed |